Weekly bryostatin-1 in metastatic renal cell carcinoma: A phase II study

Clinical Cancer Research

Volumn 9, Issue 1 I, 2003, Pages 109-114

  Haas, Naomi B ^a,d   Smith, Mitchell ^a   Lewis, Nancy ^a   Littman, Lynn ^a   Yeslow, Gwen ^a   Joshi, Indira D ^a   Murgo, Anthony ^c   Bradley, Joyce ^a   Gordon, Robert ^b   Hao, Wang ^a   Rogatko, Andre ^a   Hudes, Gary R ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b Pinnacle Cancer Center   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Department of Medical Oncology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRYOSTATIN 1; C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 6; NSC 339555; PROTEIN KINASE C INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ANOREXIA; ARTICLE; ATAXIA; BLOOD LEVEL; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG RESPONSE; DYSPNEA; EDEMA; FATIGUE; FEMALE; HEADACHE; HEART ARRHYTHMIA; HUMAN; KIDNEY CARCINOMA; MALE; METASTASIS; MUSCLE WEAKNESS; MYALGIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; URINARY FREQUENCY; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; ENZYME INHIBITORS; FEMALE; HUMANS; INTERLEUKIN-6; KIDNEY NEOPLASMS; LACTONES; MACROLIDES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN KINASE C; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 12244275670     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Greenlee, R. T., Hill-Harmon, M. B., Murray, T., and Thun, M. Cancer statistics, 2001. CA-Cancer J. Clin., 51: 15-36, 2001.
2. Linehan, W. M., Zbar, B., Bates, S. E., Zelefsky, M. J., and Yang, J. C. Cancer of the kidney and ureter. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, Ed. 6, pp. 1362-1396, 2001.
3. Buzaid, A. C., and Todd, M. B. Therapeutic options in renal cell carcinoma. Semin. Oncol., 16: 12-19, 1989.
4. Yagoda, A., Petrylak, D., and Thompson, S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol. Clin. North Am., 20: 303-323, 1993.
5. Haas, N., and Hudes, G. Genitourinary Malignancies. In: H.M. Pinedo, D. L. Longo, and B. A. Chabner (eds.), Cancer Chemotherapy, and Biologic Response Modifiers, Vol. 17, pp. 504-535. Amsterdam: Elsevier Science, 1997.
6. Bloom, H. J. Hormone induced and spontaneous regression of metastatic renal cancer. Cancer (Phila.), 32: 1066-1071, 1973.
7. Rosenberg, S. A. Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells. In: V.T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Important Advances in Oncology, pp. 217-257, Philadelphia: Lippincott, 1988.
8. Fisher, R. I., Coltman, C. A., and Doroshow, J. H. Phase II clinical trial of interleukin II plus lymphokine activated killer cells in metastatic renal cancer. Proc. Am. Soc. Clin. Oncol., 6: 244, 1987.
9. Negrier, S., Escudier, B., Lasset, C., Douillard, J-Y., Savary, J., Chevreau, C., Ravaud, A., Mercatello, A., Peny, J., Mousseau, M., Philip, T., and Tursz, T. For the Groupe Francais d'Immunotherapie. Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal-cell carcinoma. N. Engl. J. Med., 338: 1272-1275, 1998.
10. Pettit, G. R., Herald, C. L., and Doubek, D. L. Isolation and structure of bryostatin I. J. Am. Chem. Soc., 104: 6846-6848, 1982.
11. Homong, R. L., Pearson, J. W., Beckwith, M., and Longo, D. L. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res., 52: 101-107, 1992.
12. Dale, I. L., Bradshaw, T. D., Gescher, A., and Pettit, G. R. Comparison of effects of bryostatins 1 and 2 12- 0-tetradecanoylphorbol-13 acetate on PKC activity in A549 human lung carcinoma cells. Cancer Res., 49: 3242-3245, 1989.
13. Trenn, G., Pettit, G. R., Takayama, H., Hu-Li, J., and Sitkovsky, M.V. Immunomodulating properties of a novel series of protein kinase C activators: the bryostatins. J. Immunol., 140: 433-439, 1988.
14. Kraft, A. S., Reeves, J. A., and Ashendel, C. L. Differing modulation of protein kinase C by bryostatin 1 and phorbol esters in JB6 mouse epidermal cells. J. Biol. Chem., 263: 8437-8442, 1988.
15. Uhlman, D. L., Nguyen, P., Manivel, J. C., Zhang, G., Hagen, K., Fraley E., Aeppli, D., and Niehans, G. A. Epidermal growth factor receptor and transforming growth factor-α expression in papillary and non-papillary renal cell carcinoma: correlation with metastatic behavior and prognosis. Clin. Cancer Res., 1: 913-920, 1995.
16. Mydlo, J. H., Michaeli, J., Cordon-Cardo, C., Goldenberg, A. S., Heston, W. D., and Fair, W. R. Expression of transforming growth factor α and epidermal growth factor receptor messenger RNA in neoplastic and non-neoplastic human kidney tissue. Cancer Res., 49: 3407-3411, 1989.
17. Kaubisch, A., Kelsen, D. P., Saltz, L., Kemeny, N., O'Reilly, E., Ilson, D., Endres, S., Barazzuol, J., Piazza, A., and Schwartz, G. K. Phase I trial of weekly sequential bryostatin-1 (Bryo), cisplatin, and paclitaxel in pts with advanced solid tumors. Proc. Am. Soc. Clin. Oncol., 19: 230a, 2000.
18. Philip, P. A., Rea, D., Thavasu, P., Carmichael, J., Stuart, N. S., Rockett H., Talbot, D. C., Ganesan, T., Pettit, G. R., and Balkwill, F. Phase I study of bryostatin I assessment of interleukin 6 and tumor necrosis factor α induction in vivo. The Cancer Research Campaign Phase I Committee. J. Natl. Cancer Inst. (Bethesda), 85: 1812-1818, 1993.
19. Miller, A. B., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment. Cancer, 47: 207-214, 1981.
20. Babb, J., Rogatko, A., and Zacks, S. Cancer Phase I clinical trials: efficient dose escalation with overdose control. Stat. Med., 17: 1103-1120, 1998.
21. Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., and Ferrara, J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol., 17: 2530-2540, 1999.
22. Prendiville, J., Crowther, D., Thatcher, N., Woll, P. J., Fox, B. W., McGown, A., Testa, N., Stem, P., McDermott, R., and Potter, M. A Phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br. J. Cancer, 68: 418-424, 1993.
23. Jayson, G. C., Crowther, D., Prendiville, J., McGown, A. T., Scheid, C., Stem, P., Young, R., Brenchley, P., Chang, J., and Owens, S. A Phase I trial of bryostatin 1 in patients with advanced malignancy using a 24-hour intravenous infusion. Br. J. Cancer, 72: 461-468, 1995.
24. Varterasian, M., Eilender, D., and Mohammad, R. Phase I trial of bryostatin 1 in relapsed lymphoma and CLL. Proc. Am. Soc. Clin. Oncol., 15: 481, 1996.
25. Zhang, X., Zhang, R., Zhao, H., Cai, H., Gush, K. A., Kerr, R. G., Pettit, G. R., and Kraft, A. S. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. Cancer Res., 56: 802-808, 1996.
26. Blay, J. Y., Negrier, S., Combaret, V., Attali, S., Goillot, E., Merrouche, Y., Mercatello, A., Ravault, A., Tourani, J. M., and Moskovtchenko, J. F. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res., 52: 3317-3322, 1992.
27. Walther, M. M., Johnson, B., Culley, D., Shah, R., Weber, J., Venzon, D., Yang, J. C., Linehan, W. M., and Rosenberg, S. A. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin 2 correlates with paraneoplastic syndromes but not patient survival. J. Urol., 159: 718-722, 1998.
28. Pagliaro, L., Daliani, D., Amato, R., Tu, S. M., Jones, D., Smith, T., Logothetis, C., and Millikan, R. A Phase lI trial of Bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer, 89: 615-618, 2000.
29. Elson, P. J., Witte, R. S., and Trump, D. L. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res., 48: 7310-7313, 1988.